132 related articles for article (PubMed ID: 35255331)
1. Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
Mifsud W; Furtwängler R; Vokuhl C; D'Hooghe E; Pritchard-Jones K; Graf N; Vujanić GM
Eur J Cancer; 2022 May; 166():1-7. PubMed ID: 35255331
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
[TBL] [Abstract][Full Text] [Related]
3. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
[TBL] [Abstract][Full Text] [Related]
4. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
[TBL] [Abstract][Full Text] [Related]
5. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
[TBL] [Abstract][Full Text] [Related]
7. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
[TBL] [Abstract][Full Text] [Related]
9. Anaplasia in Wilms tumor: A critical review.
Vujanić GM; Mifsud W
Pediatr Blood Cancer; 2024 Jul; 71(7):e31000. PubMed ID: 38605554
[TBL] [Abstract][Full Text] [Related]
10. Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
Groenendijk A; van Tinteren H; Jiang Y; de Krijger RR; Vujanic GM; Godzinski J; Rübe C; Schenk JP; Morosi C; Pritchard-Jones K; Al-Saadi R; Vaidya SJ; Verschuur AC; Ramírez-Villar GL; Graf N; de Camargo B; Drost J; Perotti D; van den Heuvel-Eibrink MM; Brok J; Spreafico F; Mavinkurve-Groothuis AMC
Eur J Cancer; 2022 Mar; 163():88-97. PubMed ID: 35042071
[TBL] [Abstract][Full Text] [Related]
11. Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies (2001-2020).
D'Hooghe E; Furtwängler R; Chowdhury T; Vokuhl C; Al-Saadi R; Pritchard-Jones K; Graf N; Vujanić GM
Cancer; 2023 Jun; 129(12):1930-1938. PubMed ID: 36929497
[TBL] [Abstract][Full Text] [Related]
12. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
[TBL] [Abstract][Full Text] [Related]
13. Multimodal therapy for adult Wilms' tumour: an experience from one centre.
Li JJ; Huang HH; Shen J; Jiang JY; Pan F; Yu ST; Kang Y; Zhao XX; Yan XC; Liang HJ
Clin Transl Oncol; 2011 Sep; 13(9):672-6. PubMed ID: 21865139
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
[TBL] [Abstract][Full Text] [Related]
15. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.
Daw NC; Chi YY; Kalapurakal JA; Kim Y; Hoffer FA; Geller JI; Perlman EJ; Ehrlich PF; Mullen EA; Warwick AB; Grundy PE; Paulino AC; Gratias E; Ward D; Anderson JR; Khanna G; Tornwall B; Fernandez CV; Dome JS;
J Clin Oncol; 2020 May; 38(14):1558-1568. PubMed ID: 32134700
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry.
Dávila Fajardo R; Oldenburger E; Rübe C; López-Yurda M; Pritchard-Jones K; Bergeron C; Graf N; van Grotel M; van Tinteren H; Saunders D; van den Heuvel-Eibrink MM; Janssens GO; Oldenburger F
Pediatr Blood Cancer; 2018 Aug; 65(8):e27085. PubMed ID: 29693799
[TBL] [Abstract][Full Text] [Related]
17. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with Wilms' tumour stage III due to positive resection margins only: An analysis of patients treated on the SIOP-WT-2001 protocol in the UK-CCLG and GPOH studies.
Vujanić GM; Graf N; D'Hooghe E; Chowdhury T; Vokuhl C; Al-Saadi R; Pritchard-Jones K; Melchior P; Furtwängler R
Int J Cancer; 2023 Apr; 152(8):1640-1647. PubMed ID: 36444500
[TBL] [Abstract][Full Text] [Related]
19. Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
; van den Heuvel-Eibrink MM; Pritchard-Jones K; van Tinteren H; Graf N
Eur J Cancer; 2015 May; 51(8):995-6. PubMed ID: 25840668
[No Abstract] [Full Text] [Related]
20. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]